Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-09-19

Clinical Trial Update: The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies. [Phase 2]

View source ↗

Summary

The Phase 2 pemigatinib trial in patients with advanced malignancies has been terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pemazyre (pemigatinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Advanced Malignancies | Phase 2 | Status: TERMINATED | Results posted: 2024-09-19